血清GP73、ENO1及γ-GT水平对肝癌预后的预测价值

Prognostic value of serum levels of GP73,ENO1 andγ-GT in liver cancer

目的检测血清高尔基蛋白73(GP73)、α-烯醇化酶(ENO1)及γ谷氨酰胺转肽酶(γ-GT)水平,探讨其对肝癌预后的预测价值。方法选取2019年1月-2022年1月于如皋市人民医院进行治疗的86例肝癌患者为病例组,并同期选择70名健康体检人群作为对照组。病例组根据不同预后情况分为死亡组(n=28)和存活组(n=58)。分析各组血清GP73、ENO1及γ-GT水平变化,采用受试者工作特征(ROC)曲线分析GP73、ENO1和γ-GT对肝癌预后的预测价值。结果病例组血清GP73、ENO1和γ-GT水平分别为(161.87±41.08)μg/L、(74.41±23.52)ng/mL和(233.19±35.41)U/L,显著高于对照组(43.25±12.43)μg/L、(16.56±3.46)ng/mL、(24.43±7.48)U/L,差异均有统计学意义(t=23.294、20.388、48.426,P均<0.001);Ⅰ期血清GP73、ENO1和γ-GT水平分别为(115.68±42.09)μg/L、(49.58±21.15)ng/mL、(148.59±36.58)U/L,显著低于Ⅱ期(158.56±39.46)μg/L、(73.15±19.86)ng/mL、(229.58±38.96)U/L和Ⅲ期患者(191.87±40.19)μg/L、(90.00±20.16)ng/mL、(285.62±40.18)U/L,Ⅱ期患者血清GP73、ENO1及γ-GT显著低于Ⅲ期患者,差异均有统计学意义(F=21.712、24.102、74.909,P均<0.001)。死亡组血清GP73、ENO1及γ-GT水平分别为(225.29±41.29)μg/L、(145.09±30.25)ng/mL、(356.44±41.25)U/L,显著高于存活组(131.25±38.56)μg/L、(40.29±18.56)ng/mL、(173.69±40.16)U/L,差异均有统计学意义(t=14.572、25.352、27.849,P均<0.001)。ROC曲线显示,血清GP73预测肝癌的曲线下面积(AUC)为0.788,灵敏度为83.15%,特异度为84.68%,截断值为70.04μg/L;血清ENO1预测肝癌的AUC为0.810,灵敏度为83.56%,特异度为86.45%,截断值为25.03 ng/mL;血清γ-GT预测肝癌的AUC为0.955,灵敏度为88.49%,特异度为91.05%,截断值为86.95 U/L(P<0.05)。结论血清GP73、ENO1及γ-GT在肝癌患者中表达异常,且对患者预后有一定预测价值。

Objective To investigate the predictive value of Golgi protein 73(GP73),α-enolase(ENO1)andγ-glutamyl transpeptidase(γ-GT)for liver cancer prognosis.Methods A total of 86 cases of liver cancer in the Rugao People's Hospital from January 2019 to January 2022 were selected as the case group,and 70 healthy subjects were selected as the control group.The changes of serum GP73,ENO1 andγ-GT levels and their predictive value were analyzed,receiver operating characteristic(ROC)curve was used to analyze the predictive value of GP73,ENO1 andγ-GT on HCC prognosis.Results Serum levels of GP73(161.87±41.08)μg/L,ENO1(74.41±23.52)ng/mL andγ-GT(233.19±35.41)U/L in the case group were significantly higher than those in the control group(43.25±12.43)μg/L,(16.56±3.46)ng/mL,(24.43±7.48)U/L,the differences were statistically significant(t=23.294,20.388,48.426;all P<0.001).At stage I,serum GP73,ENO1 andγ-GT were(115.68±42.09)μg/L,(49.58±21.15)ng/mL and(148.59±36.58)U/L,respectively,significantly lower than those in stageⅡ(158.56±39.46)μg/L,(73.15±19.86)ng/mL,(229.58±38.96)U/L and StageⅢ(191.87±40.19)μg/L,(90.00±20.16)ng/mL,(285.62±40.18)U/L.Serum GP73,ENO1 andγ-GT in stageⅡpatients were significantly lower than those in stageⅢpatients(F=21.712,24.102,74.909;all P<0.05).Serum levels of GP73,ENO1 andγ-GT(225.29±41.29)μg/L,(145.09±30.25)ng/mL,(356.44±41.25)U/L in death group were significantly higher than those in survival group(131.25±38.56)μg/L,(40.29±18.56)ng/mL,(173.69±40.16)U/L(t=14.572,25.352,27.849;all P<0.05).ROC curve results showed that the area under the curve(AUC)of serum GP73 was 0.788,the sensitivity was 83.15%,the specificity was 84.68%,and the cut-off value was 70.04μg/L.The AUC of serum ENO1 was 0.810,the sensitivity was 83.56%,the specificity was 86.45%,and the cutoff value was 25.03 ng/mL.The AUC of serumγ-GT was 0.955,the sensitivity was 88.49%,the specificity was 91.05%,and the cutoff value was 86.95 U/L(P<0.05).Conclusion Serum GP73,eNO1 andγ-GT were abnormally expressed in patients with liver cancer,and had a certain value in evaluating the prognosis of patients.